Inhibition of Cytochrome bc 1 as a Strategy for Single-Dose, Multi-Stage Antimalarial Therapy
- 3 June 2015
- journal article
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 92 (6) , 1195-1201
Abstract
Single-dose therapies for malaria have been proposed as a way to reduce the cost and increase the effectiveness of antimalarial treatment. However, no compound to date has shown single-dose activity against both the blood-stage Plasmodium parasites that cause disease and the liver-stage parasites that initiate malaria infection. Here, we describe a subset of cytochrome bc1 (cyt bc1) inhibitors, including the novel 4(1H)-quinolone ELQ-400, with single-dose activity against liver, blood, and transmission-stage parasites in mouse models of malaria. Although cyt bc1 inhibitors are generally classified as slow-onset antimalarials, we found that a single dose of ELQ-400 rapidly induced stasis in blood-stage parasites, which was associated with a rapid reduction in parasitemia in vivo. ELQ-400 also exhibited a low propensity for drug resistance and was active against atovaquone-resistant P. falciparum strains with point mutations in cyt bc1. Ultimately, ELQ-400 shows that cyt bc1 inhibitors can function as single-dose, blood-stage antimalarials and is the first compound to provide combined treatment, prophylaxis, and transmission blocking activity for malaria after a single oral administration. This remarkable multistage efficacy suggests that metabolic therapies, including cyt bc1 inhibitors, may be valuable additions to the collection of single-dose antimalarials in current development.Keywords
This publication has 33 references indexed in Scilit:
- Severity of imported malaria: protective effect of taking malaria chemoprophylaxisMalaria Journal, 2013
- Designing the next generation of medicines for malaria control and eradicationMalaria Journal, 2013
- The global pipeline of new medicines for the control and elimination of malariaMalaria Journal, 2012
- The Spiroindolone Drug Candidate NITD609 Potently Inhibits Gametocytogenesis and Blocks Plasmodium falciparum Transmission to Anopheles Mosquito VectorAntimicrobial Agents and Chemotherapy, 2012
- Imidazolopiperazines: Lead Optimization of the Second-Generation Antimalarial AgentsJournal of Medicinal Chemistry, 2012
- Yeast dihydroorotate dehydrogenase as a new selectable marker for Plasmodium falciparum transfectionMolecular and Biochemical Parasitology, 2011
- Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malariaProceedings of the National Academy of Sciences, 2011
- Optimization of endochin-like quinolones for antimalarial activityExperimental Parasitology, 2011
- Chloroquine Is Grossly Overdosed and Overused but Well Tolerated in Guinea-BissauAntimicrobial Agents and Chemotherapy, 2009
- Antimalarial quinolones: Synthesis, potency, and mechanistic studiesExperimental Parasitology, 2008